[go: up one dir, main page]

AR128499A1 - Inhibidores de parg - Google Patents

Inhibidores de parg

Info

Publication number
AR128499A1
AR128499A1 ARP230100319A ARP230100319A AR128499A1 AR 128499 A1 AR128499 A1 AR 128499A1 AR P230100319 A ARP230100319 A AR P230100319A AR P230100319 A ARP230100319 A AR P230100319A AR 128499 A1 AR128499 A1 AR 128499A1
Authority
AR
Argentina
Prior art keywords
formula
pharmaceutically acceptable
parg
group
compound
Prior art date
Application number
ARP230100319A
Other languages
English (en)
Inventor
Paul Chang
Katherine Widdowson
Lisa J Ames
Original Assignee
Arase Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arase Therapeutics Inc filed Critical Arase Therapeutics Inc
Publication of AR128499A1 publication Critical patent/AR128499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto caracterizado porque es de fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: A es un grupo que tiene la fórmula: seleccionada del grupo de fórmulas (2); B es un grupo de fórmula (a), fórmula (b), o fórmula (c). Reivindicación 78: Una composición farmacéutica caracterizado porque comprende un compuesto de una cualquiera de las reivindicaciones 1 a 77, o una sal farmacéuticamente aceptable del mismo, y por lo menos un vehículo farmacéuticamente aceptable. Reivindicación 79: Un método para inhibir la actividad de PARG caracterizado porque comprende poner en contacto un compuesto de una cualquiera de las reivindicaciones 1 a 77, o una sal farmacéuticamente aceptable del mismo, con dicha PARG.
ARP230100319A 2022-02-14 2023-02-13 Inhibidores de parg AR128499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263309753P 2022-02-14 2022-02-14

Publications (1)

Publication Number Publication Date
AR128499A1 true AR128499A1 (es) 2024-05-15

Family

ID=85703654

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100319A AR128499A1 (es) 2022-02-14 2023-02-13 Inhibidores de parg

Country Status (10)

Country Link
US (2) US12227484B2 (es)
EP (1) EP4479387A1 (es)
JP (1) JP2025505882A (es)
KR (1) KR20240159579A (es)
CN (1) CN119013261A (es)
AR (1) AR128499A1 (es)
CA (1) CA3251360A1 (es)
IL (1) IL314887A (es)
TW (1) TW202342458A (es)
WO (1) WO2023154913A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023239344A1 (en) 2022-03-23 2024-10-10 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
WO2024254990A1 (zh) * 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
TW202517256A (zh) * 2023-09-14 2025-05-01 中國大陸商再鼎醫藥（上海）有限公司 稠合雙環雜芳基作為ｐａｒｇ抑制劑及其用途
WO2025072544A1 (en) * 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025082231A1 (zh) * 2023-10-20 2025-04-24 上海璎黎药业有限公司 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
WO2025087941A1 (en) 2023-10-23 2025-05-01 Universite De Geneve Parg inhibitors in combination with parp inhibitors and uses thereof
TW202523299A (zh) * 2023-10-26 2025-06-16 大陸商上海齊魯製藥研究中心有限公司 Parg抑制劑
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025165942A1 (en) * 2024-01-31 2025-08-07 Synnovation Therapeutics, Inc. Tricyclic compounds as parc inhibitors
WO2025245087A1 (en) * 2024-05-23 2025-11-27 Synnovation Therapeutics, Inc. Heterocyclic compounds as parg inhibitors
CN118459452B (zh) * 2024-07-10 2024-10-25 苏州国匡医药科技有限公司 一种多聚adp核糖水解酶抑制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118594A (en) 1989-06-16 1992-06-02 Eastman Kodak Company Photographic elements containing removable couplers
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
CN104869992A (zh) 2012-10-26 2015-08-26 默沙东公司 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
WO2020028221A1 (en) 2018-07-30 2020-02-06 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
TWI873187B (zh) 2019-09-20 2025-02-21 美商愛德亞生物科學公司 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物
TW202241908A (zh) 2020-12-24 2022-11-01 日商模數探索股份有限公司 四氫噻吩并嘧啶磺醯胺化合物
US20220332708A1 (en) 2021-04-06 2022-10-20 Cytokinetics, Inc. Sulfonamide compounds as cardiac sarcomere activators
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
JP2025509180A (ja) 2022-03-04 2025-04-11 上海瓔黎薬業有限公司 五員ヘテロアリール環構造含有化合物、その医薬組成物及び使用
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
EP4514803A4 (en) 2022-04-28 2026-01-28 Danatlas Pharmaceuticals Co Ltd HETEROCYCLIC AND TRICYCLIC DERIVATIVES, THEIR COMPOSITIONS AND USES
AR129339A1 (es) 2022-05-17 2024-08-14 858 Therapeutics Inc Inhibidores de parg
CA3260113A1 (en) 2022-06-29 2025-06-07 Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. FIVE-LINKED AND SIX-LINKED NITROGEN COMPOUND, AND INTERMEDIATE, PROCESS OF PREPARATION AND ASSOCIATED USE
KR20250034167A (ko) 2022-07-19 2025-03-10 에보포인트 바이오사이언시스 컴퍼니 리미티드 황 함유 헤테로방향족 고리 화합물, 이의 약학적 조성물 및 이의 용도

Also Published As

Publication number Publication date
TW202342458A (zh) 2023-11-01
EP4479387A1 (en) 2024-12-25
US12227484B2 (en) 2025-02-18
WO2023154913A1 (en) 2023-08-17
JP2025505882A (ja) 2025-02-28
IL314887A (en) 2024-10-01
US20250346564A1 (en) 2025-11-13
CA3251360A1 (en) 2023-08-17
KR20240159579A (ko) 2024-11-05
CN119013261A (zh) 2024-11-22
US20230265057A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
AR128499A1 (es) Inhibidores de parg
AR126914A1 (es) Inhibidores de ras novedosos
MX2022012714A (es) Inhibidores de la replicacion de norovirus y coronavirus.
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR127645A1 (es) Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
AR126251A1 (es) Inhibidores de cdk2
MA54458B1 (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
CR20240408A (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
CO2025001287A2 (es) Inhibidores de la proteasa principal de sars-cov2
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
SA523440403B1 (ar) Magl مثبط
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
CO5590907A2 (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento de fallo cognitivo
AR129002A1 (es) Inhibidores de egfr
AR134453A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
CL2024003177A1 (es) Inhibidores de pi3ka.
AR129883A1 (es) Compuestos tricíclicos fusionados como inhibidores de mutantes g12v de kras
AR127369A1 (es) Compuestos de quinolina como inhibidores de kras
AR129470A1 (es) Inhibidores de mek y usos de estos
AR132457A1 (es) Inhibidores de kras de 2-azabiciclo[2.2.1]heptano
AR133738A1 (es) Inhibidores de cdk2 y sus usos
AR128017A1 (es) Compuestos de pirazolopirazina como inhibidores de shp2